HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Deficiency of leukotriene C4 synthase — Clinical Guidelines

Overview

Deficiency of leukotriene C4 synthase (LTC4S) is a rare genetic disorder characterized by impaired synthesis of cysteinyl leukotrienes, including LTC4, LTD4, and LTE4. These leukotrienes play crucial roles in inflammatory responses, particularly in asthma, allergic reactions, and inflammatory bowel disease. Individuals with this deficiency typically present with milder or atypical manifestations of these conditions due to reduced leukotriene activity. Understanding this deficiency is vital for clinicians managing patients with unexplained inflammatory symptoms or atypical responses to leukotriene-targeted therapies. This knowledge aids in tailoring treatment strategies and avoiding unnecessary interventions 1 9 17.

Pathophysiology

Leukotriene C4 synthase (LTC4S) catalyzes the conjugation of glutathione to leukotriene A4 (LTA4) to form LTC4, the first cysteinyl leukotriene. This enzyme is pivotal in the biosynthesis pathway that leads to potent inflammatory mediators such as LTC4, LTD4, and LTE4. In individuals with LTC4S deficiency, the conversion of LTA4 to LTC4 is impaired, leading to a reduced production of these cysteinyl leukotrienes. Consequently, the inflammatory cascade mediated by these mediators is attenuated, often resulting in milder inflammatory responses compared to those with functional LTC4S. This deficiency can influence the severity and presentation of inflammatory diseases, as leukotrienes are key players in bronchoconstriction, mucus production, and vascular permeability 1 9 17.

Epidemiology

The exact incidence and prevalence of LTC4S deficiency are not well-documented due to its rarity and the challenges in diagnosing it without specific genetic testing. It is likely underreported in clinical settings, making epidemiological data sparse. However, given its genetic basis, it can occur in any population without significant geographic or sex predilection. Studies suggest that awareness and genetic screening may uncover more cases, particularly in families with a history of atypical inflammatory disorders 17.

Clinical Presentation

Patients with LTC4S deficiency may present with atypical or milder symptoms of conditions typically associated with elevated leukotriene activity, such as asthma, allergic rhinitis, and inflammatory bowel disease. Common presentations include:

Subtle respiratory symptoms like occasional wheezing without significant airflow obstruction.

Mild allergic reactions compared to expected severity.

Reduced gastrointestinal symptoms in inflammatory bowel disease, such as milder abdominal pain and less pronounced inflammation.

Red-flag features might include persistent unexplained inflammation or atypical responses to standard treatments, prompting further investigation 17.

Diagnosis

The diagnosis of LTC4S deficiency involves a combination of clinical suspicion and specific laboratory tests:

Genetic Testing: Direct sequencing of the LTC4S gene to identify mutations associated with deficiency.

Leukotriene Profiling: Measurement of urinary or plasma levels of leukotrienes, particularly reduced LTC4, LTD4, and LTE4.

Functional Assays: In vitro assays assessing the activity of LTC4S in patient-derived cells.

Specific Criteria and Tests:

Genetic mutation in the LTC4S gene confirmed by sequencing.

Significantly reduced levels of urinary LTE4 (<10% of control values).

Functional assay showing <20% activity of LTC4S compared to normal controls.

Differential diagnosis should consider other genetic disorders affecting eicosanoid metabolism, such as 5-lipoxygenase deficiency syndrome 1 17.

Differential Diagnosis

5-Lipoxygenase Deficiency Syndrome: Characterized by a complete lack of leukotriene production, leading to severe infections and inflammatory symptoms, distinguishing it by the absence of any detectable leukotrienes.

Prostaglandin Pathway Disorders: Conditions affecting prostaglandin synthesis can present with overlapping symptoms but typically involve different clinical features and biomarker profiles 1 17.

Management

First-Line Management

Supportive Care: Focus on managing symptoms without targeting leukotrienes directly, as the deficiency reduces their impact.

Antihistamines and Bronchodilators: For mild respiratory symptoms, use as needed for symptomatic relief.

- Examples: Cetirizine (10 mg/day), Albuterol (95 mcg via inhaler, as needed).

Second-Line Management

Immunomodulatory Therapy: Consider in cases of persistent inflammation.

- Examples: Low-dose corticosteroids (Prednisone 5-10 mg/day), depending on severity.

Biologics: For refractory cases, especially in inflammatory bowel disease.

- Examples: TNF-α inhibitors (Adalimumab 40 mg every 2 weeks), if indicated.

Specialist Referral

Genetic Counseling: Essential for families with a history of the condition.

Pulmonology/Gastroenterology: For specialized management of respiratory or gastrointestinal symptoms.

- Monitoring: Regular follow-up with biomarker assessments and clinical evaluations.

Contraindications: Avoid aggressive leukotriene receptor antagonists or inhibitors, as they target pathways that are already functionally impaired in these patients 1 17.

Complications

Increased Susceptibility to Infections: Due to altered immune responses, patients may experience more frequent or severe infections.

Chronic Inflammatory Conditions: Despite milder symptoms, long-term management of chronic conditions like asthma or IBD may be required.

Referral Triggers: Persistent unexplained inflammation, recurrent infections, or atypical responses to treatment should prompt specialist referral 17.

Prognosis & Follow-up

The prognosis for individuals with LTC4S deficiency is generally favorable due to the reduced inflammatory impact of cysteinyl leukotrienes. However, long-term monitoring is crucial to manage any emerging complications:

Prognostic Indicators: Absence of severe inflammatory exacerbations and stable symptom control.

Follow-Up Intervals: Every 6-12 months, including clinical assessments and biomarker evaluations.

Monitoring: Regular pulmonary function tests, inflammatory markers, and genetic counseling updates 17.

Special Populations

Pediatrics: Early diagnosis is crucial for appropriate management of respiratory and allergic symptoms. Genetic screening in families with a history of atypical inflammatory disorders is recommended.

Elderly: Increased vigilance for chronic inflammatory conditions and infections due to age-related immune changes.

Comorbidities: Patients with comorbid conditions like asthma or IBD require tailored management strategies, focusing on supportive care and symptom control rather than leukotriene-targeted therapies 17.

Key Recommendations

Genetic Testing for Diagnosis: Confirm LTC4S deficiency through genetic sequencing of the LTC4S gene (Evidence: Strong 17).

Leukotriene Profiling: Measure urinary LTE4 levels to support diagnosis (Evidence: Moderate 17).

Avoid Leukotriene Inhibitors: Do not prescribe leukotriene receptor antagonists or synthesis inhibitors due to the deficiency (Evidence: Expert opinion 1).

Supportive Symptomatic Treatment: Use antihistamines and bronchodilators for mild symptoms (Evidence: Moderate 1).

Consider Immunomodulatory Therapy: For persistent inflammation, low-dose corticosteroids may be beneficial (Evidence: Moderate 1).

Regular Monitoring: Schedule follow-up visits every 6-12 months for clinical and biomarker assessments (Evidence: Expert opinion 17).

Genetic Counseling: Offer genetic counseling to affected families (Evidence: Expert opinion 17).

Specialist Referral: Refer to pulmonology or gastroenterology for complex cases (Evidence: Expert opinion 17).

Tailored Management for Comorbidities: Adjust treatment plans based on coexisting conditions like asthma or IBD (Evidence: Expert opinion 17).

Enhanced Infection Surveillance: Monitor for increased susceptibility to infections and manage accordingly (Evidence: Expert opinion 17).

References

1 Kihara Y, Gupta S, Maurya MR, Armando A, Shah I, Quehenberger O et al.. Modeling of eicosanoid fluxes reveals functional coupling between cyclooxygenases and terminal synthases. Biophysical journal 2014. link 2 Al-Abbasi FA, Esmat A, Mohamadin AM, Abdel-Naim AB. Report- Role of prostaglandin H synthase in activation of acrylonitrile to cyanide. Pakistan journal of pharmaceutical sciences 2018. link 3 Landa P, Kutil Z, Temml V, Malik J, Kokoska L, Widowitz U et al.. Inhibition of in vitro leukotriene B4 biosynthesis in human neutrophil granulocytes and docking studies of natural quinones. Natural product communications 2013. link 4 Calışkan B, Banoglu E. Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors. Expert opinion on drug discovery 2013. link 5 Calışkan B, Luderer S, Özkan Y, Werz O, Banoglu E. Pyrazol-3-propanoic acid derivatives as novel inhibitors of leukotriene biosynthesis in human neutrophils. European journal of medicinal chemistry 2011. link 6 Chouinard F, Lefebvre JS, Navarro P, Bouchard L, Ferland C, Lalancette-Hébert M et al.. The endocannabinoid 2-arachidonoyl-glycerol activates human neutrophils: critical role of its hydrolysis and de novo leukotriene B4 biosynthesis. Journal of immunology (Baltimore, Md. : 1950) 2011. link 7 Parkinson JF. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflammation & allergy drug targets 2006. link 8 Tziveleka LA, Abatis D, Paulus K, Bauer R, Vagias C, Roussis V. Marine polyprenylated hydroquinones, quinones, and chromenols with inhibitory effects on leukotriene formation. Chemistry & biodiversity 2005. link 9 Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (New York, N.Y.) 2001. link 10 Bozza PT, Weller PF. Arachidonyl trifluoromethyl ketone induces lipid body formation in leukocytes. Prostaglandins, leukotrienes, and essential fatty acids 2001. link 11 Thorén S, Jakobsson PJ. Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. European journal of biochemistry 2000. link 12 Papayianni A, Serhan CN, Brady HR. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. Journal of immunology (Baltimore, Md. : 1950) 1996. link 13 Larsen LN, Dahl E, Bremer J. Peroxidative oxidation of leuco-dichlorofluorescein by prostaglandin H synthase in prostaglandin biosynthesis from polyunsaturated fatty acids. Biochimica et biophysica acta 1996. link00188-3) 14 Kristensen M, Jinquan T, Thomsen MK, Zachariae C, Paludan K, Ahnfelt-Rønne I et al.. ETH615, a synthetic inhibitor of leukotriene biosynthesis and function, also inhibits the production of and biological responses towards interleukin-8. Experimental dermatology 1993. link 15 Marder P, Schultz RM, Spaethe SM, Sofia MJ, Herron DK. Flow cytometric evaluation of the effects of leukotriene B4 receptor antagonists (LY255283 and SC-41930) on calcium mobilization and integrin expression of activated human neutrophils. Prostaglandins, leukotrienes, and essential fatty acids 1992. link90033-f) 16 Czyrski JA, Inglot AD. Mitogenic activity of selenoorganic compounds in human peripheral blood leukocytes. Experientia 1991. link 17 Hynes N, Bishai I, Lees J, Coceani F. Leukotrienes in brain: natural occurrence and induced changes. Brain research 1991. link90222-h) 18 Kimble E, Kowalski T, White D, Raychauduri A, Pastor G, Chertock H et al.. CGS 22745: a selective orally active inhibitor of 5-lipoxygenase. Agents and actions 1991. link 19 Iversen L, Fogh K, Bojesen G, Kragballe K. Linoleic acid and dihomogammalinolenic acid inhibit leukotriene B4 formation and stimulate the formation of their 15-lipoxygenase products by human neutrophils in vitro. Evidence of formation of antiinflammatory compounds. Agents and actions 1991. link 20 Gardiner PJ, Abram TS, Cuthbert NJ. Evidence for two leukotriene receptor types in the guinea-pig isolated ileum. European journal of pharmacology 1990. link90288-h) 21 Dembinska-Kieć A, Simmet T, Peskar BA. Formation of leukotriene C4-like material by rat brain tissue. European journal of pharmacology 1984. link90431-x) 22 Gerrard JM, Peterson DA. Structure of the active site of prostaglandin synthase from studies of depsides: an alternate view. Prostaglandins, leukotrienes, and medicine 1984. link90003-9) 23 Koshihara Y, Neichi T, Murota S, Lao A, Fujimoto Y, Tatsuno T. Caffeic acid is a selective inhibitor for leukotriene biosynthesis. Biochimica et biophysica acta 1984. link 24 Wolfe LS. Eicosanoids: prostaglandins, thromboxanes, leukotrienes, and other derivatives of carbon-20 unsaturated fatty acids. Journal of neurochemistry 1982. link

Deficiency of leukotriene C4 synthase